Acelyrin, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mina Kim
- Full Time Employees
- 83
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4149 Liberty Canyon Road Agoura Hills CA United States of America 91301
- IPO Date
- May 4, 2023
- CIK
- 0001962918
- Website
- acelyrin.com
- Similar Companies
- Business
- Acelyrin, Inc. (Nasdaq: SLRN) is a late-stage clinical biopharmaceutical company that identifies, acquires, and accelerates the development and commercialization of transformative medicines, primarily for immunology and endocrine indications. The company develops a pipeline of product candidates including izokibep, a subcutaneous small protein therapeutic that potently inhibits IL-17A and is in Phase 3 trials for hidradenitis suppurativa, psoriatic arthritis, and non-infectious uveitis, as well as Phase 2 trials for axial spondyloarthritis; lonigutamab, a subcutaneously administered monoclonal antibody targeting IGF-1R in Phase 2/3 trials for thyroid eye disease; and SLRN-517, a monoclonal antibody targeting c-KIT in preclinical development for chronic urticaria. Founded in 2020 and headquartered in Agoura Hills, California, Acelyrin operates in the United States with a focus on patients suffering from chronic inflammatory and autoimmune diseases. In February 2025, Acelyrin entered a definitive all-stock merger agreement with Alumis Inc. to create a combined clinical biopharma entity advancing therapies for immune-mediated diseases, with the transaction approved by Acelyrin stockholders in May 2025 and completed later that month, resulting in the combined company continuing under the Alumis name. The merger followed the rejection of an unsolicited $3.00-per-share cash acquisition proposal from Concentra Biosciences in early 2025, which the board deemed inferior to the Alumis transaction; post-merger, the entity holds approximately $737 million in cash to fund programs into 2027, integrating Acelyrin's immunology assets with Alumis' TYK2 inhibitors such as ESK-001 in Phase 3 for plaque psoriasis.
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript